Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia

Gong, Jing; Dong, Hui; Qing, Xiao; Huang, Zhaoyi; Wang, Dingkun; Zhao, Yan; Liu, Wenhua; Tu, Shenghao; Zhang, Mingmin; Wang, Qi; Lu, Fanghong

doi:10.1101/2020.02.25.20025643

Cited by 245 publications

(273 citation statements)

References 10 publications

Supporting

Mentioning

253

Contrasting

Unclassified

Order By: Relevance

“…This compassionate-use program was initiated to understand the feasibility of suppressing CRP production with siltuximab and improving the outcomes in patients with COVID-19 requiring CPAP or NIV for pneumonia/ARDS treatment. Initial evidence from China where the first cases of COVID-19 emerged, indicate that excessive production inflammatory markers, such as IL-6 and CRP, correlate with severity of disease (Chen X et al 2020;Conti P et al 2020;Diao B et al 2020;Gong J et al 2020;Liu et al 2020;Yang et al 2020), and many more studies report a significant increase in IL-6 or CRP levels in patients with severe or critical COVID-19 compared with those patients with mild disease (Cai et al 2020;Chen J et al 2020;Feng C et al 2020;Huang Y et al 2020;Liu J et al 2020;Qin C et al 2020;Ruan Q et al 2020;Shi Y et al 2020;Wang Y et al 2020;Wang Z et al 2020;Wu C et al2020;Xu W et al 2020;Xu X et al 2020;Zeng Q et al 2020;Zhao Z et al 2020;Zhang B et al 2020;Zhou F et al 2020;Zhou Y et al 2020).…”

Section: Discussionmentioning

confidence: 99%

IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study

Gritti

Raimondi

Ripamonti

et al. 2020

Preprint

149

135

View full text Add to dashboard Cite

COVID-19 is caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SAR-CoV-2), resulting in symptoms, such as fever, cough, and shortness of breath. The SARS-CoV-2 virus has also been suggested to initiate a cytokine storm in patients with COVID-19 evidenced by elevated cytokines, such as interleukin-6 (IL-6) and Creactive protein (CRP).We report preliminary data from 21 patients with COVID-19 who developed pneumonia/acute respiratory distress syndrome (ARDS) and participated in a compassionate-use program at Papa Giovanni XXIII hospital in Bergamo, Italy.All 21 patients received intravenous siltuximab -a chimeric mAb that binds to and blocks the effect of IL-6 -at a dose ranging between 700 to 1,200 mg (median 900 mg). The median age of patients treated was 64 years, and all patients were followed for a median of eight days. Serum CRP levels reduced in all 16 patients with available . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

show abstract

Section: Discussionmentioning

confidence: 99%

IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study

Gritti

Raimondi

Ripamonti

et al. 2020

Preprint

149

135

View full text Add to dashboard Cite

show abstract

“…In terms of laboratory test results, lymphocytes, especially T lymphocytes were significantly reduced in severe cases, which indicates COVID-19 consumed immune cells and inhibits the cellular immune function. In addition, progressive patients tend to have higher baseline NLR, ESR, CRP, IL-6, D-dimer level, which may be related to inflammatory response and cytokine storm induced by virus invasion [17,18]. Those inflammatory factors level at admission may help to identify and determine later clinical progression.…”

Section: Discussionmentioning

confidence: 99%

The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China

Wang

Zhou

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background The novel coronavirus disease 2019(COVID-19) broke out globally. Early prediction of the clinical progression was essential but still unclear. We aimed to evaluate the timeline of COVID-19 development and analyze risk factors of disease progression.Methods In this retrospective study, we included 333 patients with laboratory-confirmed COVID-19 infection hospitalized in the Third People's Hospital of Shenzhen from 10 January to 10 February 2020. Epidemiological feature, clinical records, laboratory and radiology manifestations were collected and analyzed. 323 patients with mild-moderate symptoms on admission were observed to determine whether they exacerbated to severe-critically ill conditions (progressive group) or not (stable group). We used logistic regression to identify the risk factors associated with clinical progression.Results Of all the 333 patients, 70(21.0%) patients progressed into severe-critically ill conditions during hospitalization and assigned to the progressive group, 253(76.0%) patients belonged to the stable group, another 10 patients were severe before admission. we found that the clinical features of aged over 40 (3.80[1.72, 8.52]), males (2.21[1.20, 4.07]), with comorbidities (1.78[1.13, 2.81]) certain exposure history (0.38[0.20, 0.71]), abnormal radiology manifestations (3.56[1.13, 11.40]), low level of T lymphocytes (0.99[0.997, 0.999]), high level of NLR (0.99[0.97, 1.01]), IL-6 (1.05[1.03, 1.07]) and CRP (1.67[1.12, 2.47]) were the risk factors of disease progression by logistic regression.Conclusions the potential risk factors of males, older age, with comorbidities, low T lymphocyte level and high level of NLR, CRP, IL-6 can help to predict clinical progression of COVID-19 at an early stage.

show abstract

“…Rapid pulmonary deterioration in COVID-19 is due to a systemic/pulmonary inflammatory response associated with increased serum IL-6, IL-8 and TNF- levels. (36) The potential role of corticosteroids for the prevention of progression of mild COVID-19 to severe pneumonia is unknown. The World Health Organization recommends avoiding corticosteroids for treatment of COVID-19 unless indicated for another therapeutic purpose.…”

Section: Management Of Patients On Immunosuppressive Agentsmentioning

confidence: 99%

Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID‐19 Pandemic: AASLD Expert Panel Consensus Statement

et al. 2020

View full text Add to dashboard Cite

Background and Aims Coronavirus disease 2019 (COVID‐19), the illness caused by the SARS‐CoV‐2 virus, is rapidly spreading throughout the world. Hospitals and healthcare providers are preparing for the anticipated surge in critically ill patients, but few are wholly equipped to manage this new disease. The goals of this document are to provide data on what is currently known about COVID‐19, and how it may impact hepatologists and liver transplant providers and their patients. Our aim is to provide a template for the development of clinical recommendations and policies to mitigate the impact of the COVID‐19 pandemic on liver patients and healthcare providers. Approach and Results This article discusses what is known about COVID‐19 with a focus on its impact on hepatologists, liver transplant providers, patients with liver disease, and liver transplant recipients. We provide clinicians with guidance for how to minimize the impact of the COVID‐19 pandemic on their patients’ care. Conclusions The situation is evolving rapidly, and these recommendations will need to evolve as well. As we learn more about how the COVID‐19 pandemic impacts the care of patients with liver disease, we will update the online document available at https://www.aasld.org/about-aasld/covid-19-and-liver.

show abstract

Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia

Cited by 245 publications

References 10 publications

IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study

IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study

The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China

Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID‐19 Pandemic: AASLD Expert Panel Consensus Statement

Contact Info

Product

Resources

About